[go: up one dir, main page]

CY1113435T1 - Φαρμακευτικη συνθεση που περιλαμβανει παραγωγο πυραζινης, και μεθοδος χρησης παραγωγου πυραζινης σε συνδυασμο - Google Patents

Φαρμακευτικη συνθεση που περιλαμβανει παραγωγο πυραζινης, και μεθοδος χρησης παραγωγου πυραζινης σε συνδυασμο

Info

Publication number
CY1113435T1
CY1113435T1 CY20121101175T CY121101175T CY1113435T1 CY 1113435 T1 CY1113435 T1 CY 1113435T1 CY 20121101175 T CY20121101175 T CY 20121101175T CY 121101175 T CY121101175 T CY 121101175T CY 1113435 T1 CY1113435 T1 CY 1113435T1
Authority
CY
Cyprus
Prior art keywords
producer
pyrazine
pharmaceutical composition
combination
composition including
Prior art date
Application number
CY20121101175T
Other languages
English (en)
Inventor
Masako Maekawa
Original Assignee
Toyama Chemical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toyama Chemical Co., Ltd. filed Critical Toyama Chemical Co., Ltd.
Publication of CY1113435T1 publication Critical patent/CY1113435T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Φανερώνεται μία φαρμακευτική σύνθεση που περιλαμβάνει ένα παράγωγο πυραζίνης που παριστάνεται με τον γενικό τύπο:
CY20121101175T 2007-02-16 2012-12-03 Φαρμακευτικη συνθεση που περιλαμβανει παραγωγο πυραζινης, και μεθοδος χρησης παραγωγου πυραζινης σε συνδυασμο CY1113435T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007035975 2007-02-16
EP08711267A EP2123276B1 (en) 2007-02-16 2008-02-14 Pharmaceutical composition comprising pyrazine derivative, and method of using pyrazine derivative in combination

Publications (1)

Publication Number Publication Date
CY1113435T1 true CY1113435T1 (el) 2016-06-22

Family

ID=39690101

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20121101175T CY1113435T1 (el) 2007-02-16 2012-12-03 Φαρμακευτικη συνθεση που περιλαμβανει παραγωγο πυραζινης, και μεθοδος χρησης παραγωγου πυραζινης σε συνδυασμο

Country Status (21)

Country Link
US (1) US8759354B2 (el)
EP (1) EP2123276B1 (el)
JP (1) JP5255456B2 (el)
KR (1) KR101479083B1 (el)
CN (1) CN101610772B (el)
AU (1) AU2008215397B2 (el)
BR (1) BRPI0807597B8 (el)
CA (1) CA2677905C (el)
CY (1) CY1113435T1 (el)
DK (1) DK2123276T3 (el)
ES (1) ES2396595T3 (el)
HR (1) HRP20130111T1 (el)
IL (1) IL200285A (el)
MX (1) MX2009008779A (el)
NZ (1) NZ578989A (el)
PL (1) PL2123276T3 (el)
PT (1) PT2123276E (el)
RU (1) RU2463051C2 (el)
SI (1) SI2123276T1 (el)
WO (1) WO2008099874A1 (el)
ZA (1) ZA200905536B (el)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2417617A4 (en) * 2009-04-09 2012-09-26 Lg Electronics Inc DISPLAY APPARATUS
EP2975409B1 (en) * 2010-05-10 2018-10-31 Academia Sinica Zanamivir phosphonate congeners with anti-influenza activity and determining oseltamivir susceptibility of influenza viruses
JP5936546B2 (ja) 2010-09-30 2016-06-22 富山化学工業株式会社 ６−フルオロ−３−ヒドロキシ−２−ピラジンカルボキサミドのメグルミン塩
ES2554630T3 (es) 2010-09-30 2015-12-22 Toyama Chemical Co., Ltd. Sal sódica de 6-fluoro-3-hidroxi-2-pirazinocarboxamida
AT510585B1 (de) 2010-11-18 2012-05-15 Apeptico Forschung & Entwicklung Gmbh Zusammensetzung umfassend ein peptid und ein hemmstoff der viralen neuraminidase
WO2014186465A1 (en) * 2013-05-14 2014-11-20 Biocryst Pharmaceuticals, Inc. Anti-influenza compositions and methods
CN104447583B (zh) * 2014-11-20 2016-08-24 广东东阳光药业有限公司 含有环丁烷取代基的吡嗪类化合物及其组合物及用途
CN104447585B (zh) * 2014-11-20 2016-08-24 广东东阳光药业有限公司 吡嗪类化合物及其组合物及用途
CN104447584B (zh) * 2014-11-20 2016-08-24 广东东阳光药业有限公司 含有环丁烷取代基的吡嗪类化合物及其组合物及用途
CN104402833B (zh) * 2014-11-20 2016-08-24 广东东阳光药业有限公司 含有环丁烷取代基的吡嗪类化合物及其组合物及用途
CN104496918B (zh) * 2014-12-10 2016-08-24 广东东阳光药业有限公司 吡嗪衍生物及其用途
CN104817511B (zh) * 2015-04-27 2017-04-19 济南大学 一种丁烯二酸酐制备法匹拉韦关键中间体的方法
KR102084109B1 (ko) * 2015-12-15 2020-03-03 시오노기세야쿠 가부시키가이샤 캡 의존적 엔도뉴클레아제 저해제 및 항인플루엔자 약을 조합하는 것을 특징으로 하는 인플루엔자 치료용 의약
WO2020138067A1 (ja) 2018-12-25 2020-07-02 富士フイルム富山化学株式会社 ピラジン誘導体と細胞内におけるピラジン誘導体リボース三リン酸体の量を増加させる化合物とを組み合わせてなるｒｎａウイルス感染症治療剤
EP4159215A4 (en) 2020-05-27 2023-11-22 FUJIFILM Toyama Chemical Co., Ltd. THERAPEUTIC AGENT FOR RNA VIRAL INFECTION OBTAINED BY COMBINATION OF A PYRAZINE DERIVATIVE AND A THIOPURINE DERIVATIVE

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01197437A (ja) * 1988-01-29 1989-08-09 Dso Pharmachim 抗ウイルス薬
RU2224520C2 (ru) * 1998-08-20 2004-02-27 Тояма Кемикал Ко., Лтд. Азотсодержащие гетероциклические производные карбоксамида или их соли и противовирусные средства, включающие их
WO2003015798A1 (en) 2001-08-14 2003-02-27 Toyama Chemical Co., Ltd. Novel virus proliferation inhibition/virucidal method and novel pyradine nucleotide/pyradine nucleoside analogue
JP2005354833A (ja) * 2004-06-11 2005-12-22 Fujinon Corp アクチュエータ
JP4689989B2 (ja) * 2004-08-27 2011-06-01 オリンパス株式会社 振動波リニアモータ及びそれを用いたレンズ装置
DE102008031715A1 (de) 2008-07-04 2010-01-07 Henkel Ag & Co. Kgaa Haarkonditionierende Mittel mit Imidazolinen

Also Published As

Publication number Publication date
KR20090121289A (ko) 2009-11-25
MX2009008779A (es) 2009-11-05
NZ578989A (en) 2011-07-29
ES2396595T3 (es) 2013-02-22
AU2008215397B2 (en) 2012-09-06
AU2008215397A1 (en) 2008-08-21
EP2123276B1 (en) 2012-11-28
CN101610772B (zh) 2013-01-16
RU2009134516A (ru) 2011-03-27
EP2123276A4 (en) 2011-05-18
US8759354B2 (en) 2014-06-24
BRPI0807597A2 (pt) 2014-05-06
BRPI0807597B8 (pt) 2021-05-25
EP2123276A1 (en) 2009-11-25
RU2463051C2 (ru) 2012-10-10
IL200285A0 (en) 2010-04-29
JPWO2008099874A1 (ja) 2010-05-27
BRPI0807597B1 (pt) 2021-03-02
JP5255456B2 (ja) 2013-08-07
CA2677905C (en) 2015-03-24
IL200285A (en) 2014-06-30
CN101610772A (zh) 2009-12-23
PL2123276T3 (pl) 2013-04-30
KR101479083B1 (ko) 2015-01-07
ZA200905536B (en) 2010-10-27
HRP20130111T1 (hr) 2013-02-28
US20100087447A1 (en) 2010-04-08
WO2008099874A1 (ja) 2008-08-21
SI2123276T1 (sl) 2013-03-29
DK2123276T3 (da) 2013-01-02
PT2123276E (pt) 2013-01-16
CA2677905A1 (en) 2008-08-21

Similar Documents

Publication Publication Date Title
CY1113435T1 (el) Φαρμακευτικη συνθεση που περιλαμβανει παραγωγο πυραζινης, και μεθοδος χρησης παραγωγου πυραζινης σε συνδυασμο
CY1117143T1 (el) Νεα καρβονυλιωμενα (αζα)κυκλοεξανια ως προσδετες του d3 υποδοχεα ντοπαμινης
CY1120961T1 (el) Δοσολογικες μορφες απο του στοματος που περιλαμβανουν αντιαιμοπεταλιακο παραγοντα και αναστολεα οξεος
CY1113102T1 (el) Ενωσεις φαινυλπροπιοναμιδιου και η χρηση αυτων
NI201100223A (es) Derivados de imidazolidina 2 -0ne 1,3 - disustituidos como inhibidores de cyp 17
CY1112495T1 (el) Κυτταροτοξικοι παραγοντες που περιλαμβανουν νεα παραγωγα τομαϋμυκινης
CY1118680T1 (el) Φαρμακευτικη συνθεση
CY1114988T1 (el) Βενζοδιαζεπινη αναστολεας bromodomain
ECSP11010760A (es) Derivados de quinoxalindiona
CR11861A (es) Compuestos organicos
CY1115262T1 (el) Ανταγωνιστες trpv1 και χρησεις αυτων
CY1112813T1 (el) 4-(4-κυανο-2-θειοαρυλ)διϋδροπυριμιδινονες και η χρηση αυτων
CO6450612A2 (es) Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750
BRPI0606112A2 (pt) 3 - heteroaril - 3 - hidróxi - 2 - amino - propil aminas e compostos relacionados, bem como uso dos mesmos e composição farmacêutica
CY1110026T1 (el) Ενωσεις πιπεραζινης βενζισοξαζολης και μεθοδοι χρησης εξ αυτων
DE602008000754D1 (de) Tropanverbindungen
CY1113024T1 (el) Σπειροκυκλικα παραγωγα κυκλοεξανιου για τη θεραπεια της εξαρτησης ουσιων
CY1113485T1 (el) Ενωσεις γεφυρωμενης-πιπεριδινης τυπου υποκατεστημενης-κινοξαλινης και οι χρησεις εξ' αυτων
CY1113916T1 (el) Παραγωγα ετεροαρυλο πυρρολιδινυλο και πιπεριδινυλο κετονης
CO6382123A2 (es) Antagonistas de la via hedgehog de ftalazina disustituida
CR20110403A (es) Derivados de tiadiazoles y oxadiazoles, su preparación y su aplicación en terapia
CY1111954T1 (el) Παραγωγα τετραϋδροναφθαλινιου, μεθοδοι για την παραγωγη αυτων και η χρηση αυτων ως αντιφλεγμονωδη
CY1115623T1 (el) Μεθοδος για την συνθεση 7,8-διμεθοξυ-1,3-διϋδρο-2η-3-βενζαζεπιν-2-ονης και εφαρμογη αυτης στη συνθεση της ιβαμπραδινης καθως επισης αλατων προσθηκης αυτης με ενα φαρμακευτικως αποδεκτο οξυ
EA200801676A1 (ru) Комбинация производных триазина и сенсибилизаторов инсулина
CY1113551T1 (el) Υποκατεστημενες ενωσεις νικοτιναμιδιου και η χρησιμοποιηση τους σε φαρμακα